Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now
Exact Sciences Corporation (NASDAQ: EXAS) has turned into one of the most closely watched healthcare stocks heading into December 2025, thanks to a blockbuster takeover agreement with Abbott Laboratories, strong Q3 results, and a rapid share‑price rally that has pushed EXAS to all‑time highs. As of mid‑day on December 1, 2025, the stock trades around $101 per share, just below the agreed $105 per‑share cash buyout price. Exact Sciences Investor Relations+1 Below is a deep dive into the latest news, earnings, analyst forecasts, and key risks around Exact Sciences stock as of December 1, 2025. Exact Sciences Stock Today: Trading